No Data
No Data
Wuzhou Zhongheng Unit Gets Nod to Amend Naloxone Hydrochloride Injection
Express News | Guangxi Wuzhou Zhongheng Group: The holding subsidiary Chongqing Lummy Pharmaceutical has received the approval notice for the supplementary application of Naloxone Hydrochloride Injection.
Core product revenue declines. Where will Guangxi Wuzhou Zhongheng Group's new profit growth points be?| Directly addressing the Earnings Conference.
① Due to the significant drop in price of the company's core product, thrombolytic injection, the performance of Guangxi Wuzhou Zhongheng Group continues to decline. ② The company's management indicated that in addition to internal growth, they will also achieve external expansion through mergers and acquisitions in the future, with a focus on the layout of Traditional Chinese Medicine, research and development, business development, and the supporting medical instruments sector.
Guangxi Wuzhou Zhongheng Group (600252.SH): has cumulatively repurchased 1.2720% of the company's shares.
According to Ge Long Hui on May 6th, Guangxi Wuzhou Zhongheng Group (600252.SH) announced that as of April 30, 2025, the company has repurchased a total of 42,146,997 shares of the company through the centralized bidding trading method on the Shanghai Stock Exchange, accounting for 1.2720% of the current total share capital of 3,313,345,567 shares. The highest price of the repurchase was 2.44 yuan/share, the lowest price was 2.30 yuan/share, and the total amount of funds paid was 100,621,045.92 yuan (excluding stamp duty, transaction commissions, and other trading fees).
Zhongheng Group: Guangxi Wuzhou Zhongheng Group Co., Ltd. report for the first quarter of 2025
Guangxi Wuzhou Zhongheng Group Co., Ltd. Report for the first quarter of 2025